ARC AAT

Drug Profile

ARC AAT

Alternative Names: ARC-AAT; ARO AAT

Latest Information Update: 16 Dec 2016

Price : $50

At a glance

  • Originator Arrowhead Research Corporation
  • Developer Arrowhead Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Alpha 1-antitrypsin deficiency
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alpha 1-antitrypsin deficiency

Most Recent Events

  • 02 Dec 2016 Arrowhead Pharmaceuticals withdraws prior to enrolment a phase II trial in Alpha 1-antitrypsin deficiency in Sweden, Italy, Ireland and Canada (IV) (NCT02900183)
  • 29 Nov 2016 Discontinued - Phase-I for Alpha 1-antitrypsin deficiency in Australia, Germany, Netherlands and United Kingdom (IV) due to company shifting its focus on on the development of RNAi therapeutics utilising its subcutaneous (subQ) and extra-hepatic delivery systems
  • 29 Nov 2016 Discontinued - Phase-II for Alpha 1-antitrypsin deficiency in Sweden, Canada, Italy, Ireland (IV) due to company shifting its focus on on the development of RNAi therapeutics utilising its subcutaneous (subQ) and extra-hepatic delivery systems
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top